Federal Reserve reduces the interest rate by another quarter point to the target range of 1.75%-2% in September 2019.

John Fourier

2019-10-07 12:35:00 Mon ET

Federal Reserve reduces the interest rate by another key quarter point to the target range of 1.75%-2% in September 2019. In accordance with the Federal Reserve dot plot of interest rate expectations, 5 FOMC members favor the prior status quo of 2% to 2.25%.

The same flagship dot plot suggests that 5 FOMC members support a quarter point cut with no more rate cuts through the remainder of the current calendar year. The dot plot further indicates that 7 FOMC members support at least one more interest rate cut in late-2019. The U.S. monetary policy committee cites the implications of global trade frictions and other regional clouds of both fiscal policy uncertainty and asset price normalization for the current economic outlook. Low inflation remains the root cause of the second interest rate cut. The recent dovish monetary policy stance accords with the Federal Reserve dual mandate of maximum sustainable employment and price stability.

Federal Reserve Chair Jerome Powell indicates that it may be essential for most market participants to raise the bar for any further interest rate reductions due to tighter financial constraints in the foreseeable future. Data dictate future moderate moves in the monetary policy space.

 


If any of our AYA Analytica financial health memos (FHM), blog posts, ebooks, newsletters, and notifications etc, or any other form of online content curation, involves potential copyright concerns, please feel free to contact us at service@ayafintech.network so that we can remove relevant content in response to any such request within a reasonable time frame.

Blog+More

The Trump administration initiates a new investigation into China's abuse of American intellectual property.

Olivia London

2017-08-31 09:36:00 Thursday ET

The Trump administration initiates a new investigation into China's abuse of American intellectual property.

The Trump administration has initiated a new investigation into China's abuse of American intellectual property under Section 301 of the Trade Act of 19

+See More

Net neutrality rules continue to revolve around the Trump administration's current IT agenda of 5G telecom transformation.

Becky Berkman

2018-05-15 08:40:00 Tuesday ET

Net neutrality rules continue to revolve around the Trump administration's current IT agenda of 5G telecom transformation.

Net neutrality rules continue to revolve around the Trump administration's current IT agenda of 5G telecom transformation. Republican Senate passes the

+See More

David Solomon succeeds Lloyd Blankfein as the new CEO of Goldman Sachs.

Fiona Sydney

2018-03-09 08:33:00 Friday ET

David Solomon succeeds Lloyd Blankfein as the new CEO of Goldman Sachs.

David Solomon succeeds Lloyd Blankfein as the new CEO of Goldman Sachs. Unlike his predecessors Lloyd Blankfein and Gary Cohn, Solomon has been an investmen

+See More

U.K. prime minister Boris Johnson encounters Brexit defeat during his new premiership.

Chanel Holden

2019-10-15 09:13:00 Tuesday ET

U.K. prime minister Boris Johnson encounters Brexit defeat during his new premiership.

U.K. prime minister Boris Johnson encounters defeat during his new premiership. The first major vote would pave the path of least resistance to passing a no

+See More

Conor McGregor learns a major money lesson from LeBron James.

Daisy Harvey

2019-08-07 12:33:00 Wednesday ET

Conor McGregor learns a major money lesson from LeBron James.

Conor McGregor learns a major money lesson from LeBron James. This lesson suggests that James spends about $1.5 million on his own body each year. The $1.5

+See More

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history.

Jacob Miramar

2019-01-10 17:31:00 Thursday ET

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history.

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history. The resultant biopharma goliath would be

+See More